



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/578,589	12/13/2006	Anne-Sophie Bessis	65517(53196)	9455
21874	7590	06/12/2009	EXAMINER	
EDWARDS ANGELL PALMER & DODGE LLP				SOLOLA, TAOFIQ A
P.O. BOX 55874		ART UNIT		PAPER NUMBER
BOSTON, MA 02205				1625
		MAIL DATE		DELIVERY MODE
		06/12/2009		PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/578,589	BESSIS ET AL.	
	Examiner	Art Unit	
	Taofiq A. Solola	1625	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) Responsive to communication(s) filed on _____.
- 2a) This action is **FINAL**. 2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) Claim(s) 1-30 and 33-43 is/are pending in the application.
 - 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) Claim(s) _____ is/are allowed.
- 6) Claim(s) _____ is/are rejected.
- 7) Claim(s) _____ is/are objected to.
- 8) Claim(s) 1-30, 33-43 are subject to restriction and/or election requirement.

Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____ .
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)	5) <input type="checkbox"/> Notice of Informal Patent Application
Paper No(s)/Mail Date _____ .	6) <input type="checkbox"/> Other: _____ .

Art Unit: 1625

Claims 1-30, 33-43, are pending in this application.

Claims 31-32 are deleted.

DETAILED ACTION

Election/Restriction

Claims 1-30, 33-43, are drawn to more than one inventive concept (as defined by PCT Rule 13) and, accordingly, a restriction is required according to the provision of PCT Rule 13.2.

PCT Rule 13.1 states that the international application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept (requirement of unity of invention).

PCT Rule 13.2 states that unity of invention referred to in Rule 13.1 shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features.

Annex B, Part 1(b), provides that special technical features mean those technical features which, as a whole, define a contribution over the prior art (novelty and unobviousness).

I. Claims 1-20, 41-42 in part, drawn to compounds of formula I and composition thereof, wherein A is 1,2,4-oxadiazol-5-yl; B is C(O) [C(O)Co-C₂alkyl]; P and Q are each phenyl; and W is piperidin-1-yl, classifiable in class 540, and subclass 106+.

II. Claims 1-20, 41-42 in part, drawn to compounds of formula I and composition thereof, wherein A is 1,2,4-oxadiazol-5-yl; B is C(O) [C(O)Co-C₂alkyl]; P is phenyl; Q is thiophene-2-yl, thiazol-2-yl, thiazole-5-yl, pyrrole-2-yl; and W is piperidin-1-yl, classifiable in class 544, and subclass 376+.

III. Claims 1-20, 41-42 in part, drawn to compounds of formula I and composition thereof, wherein A is 1,2,4-oxadiazol-5-yl; B is C(O) [C(O)Co-C₂alkyl]; P is phenyl; Q is isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, 1,2,3-thiadiazole-4-yl, classifiable in class 548, and subclass 448+.

IV. Claims 1-20, 41-42 in part, drawn to compounds of formula I and composition thereof, wherein A is 1,2,4-oxadiazol-5-yl; B is C(O) [C(O)Co-C₂alkyl]; P is phenyl; Q is pyrazol-3-yl, triazole-4-yl, classifiable in class 546, and subclass 250+.

Art Unit: 1625

V. Claims 1-20, 41-42 in part, drawn to compounds of formula I and composition thereof, wherein A is 1,2,4-oxadiazol-5-yl; B is C(O) [C(O)Co-C₂alkyl]; one of P and Q is phenyl, the other is pyridine-3-yl, classifiable in class 548, and subclass 248+. Applicant must identify which one of P and Q is phenyl.

VI. Claims 1-20, 41-42 in part, drawn to compounds of formula I and composition thereof, wherein A is 1,2,4-triazol-2-yl; B is C(O) [C(O)Co-C₂alkyl]; P and phenyl are each phenyl, classifiable in class 546, and subclass 126+.

VII. Claims 1-20, 41-42 in part, drawn to none of the compounds above but other species of compounds of formula I, within the scope of the claims. The species must be disclosed in the specification. Structures of the species must be submitted and the species identified in the specification. This group may be subject to further restriction. Cannot be classified until species are known.

VIII. Claims 21-30, 33-40, 43, drawn to methods of using compounds of formula I, classifiable in class 514, and numerous subclasses.

1. In the instant inventions, there is no structural element(s) shared by groups I-VIII (only bonds are between the variables in formula I). Therefore, under PCT Rules 13.1 and 13.2, there is no special technical feature among the groups.

2. If Group VIII is elected or in a rejoinder thereof, applicant must elect a specific disease having support in the specification and group VIII would be examined commensurate with the elected disease.

If group VIII is elected, applicant must elect a group from among I-VII, and group VIII would be examined commensurate in scope with the elected group among I-VI.

Selection of a Species

3. In an election of any of Groups I-VIII, a provisional election of a single compound is further required including an exact definition of each substitution on the base molecule (Formula #), wherein a single member at each substituent group or moiety is selected. For example, if a base molecule has a substituent group R1, wherein R1 is recited to be any one of H, OH, COOH, aryl, alkoxy, halogen, amino, etc., then applicant must select a single substituent of R1, for example OH or aryl, and each subsequent variable position.

In the instant case, Applicant must elect one representative for each ring and their substituents in formula I, and the point of attachment of each elected ring and substituent must be specified. The elected substituents must be specific not generic. The parts of the elected species corresponding to the substituents in the applicable formula must be identified.

Art Unit: 1625

Examination will then proceed on the elected species. Per MPEP 803.02, if the elected species is found unpatentable, the provisional election will be given effect and all other claimed species will be withdrawn from consideration. If the elected species is found allowable, the search will be expanded by the Examiner to other species and subgeneric compounds within the elected group until:

- I. A prior art is found.
- II. Compounds of the elected invention are found to lack unity of invention. See above.
- III. All the compounds of the elected group are searched or to the extent necessary to determine patentability. MPEP 803.02.

In accordance with the decisions in *In re Weber*, 198 USPQ 328 (CCPA 1978) and *In re Haas*, 198 USPQ 334 (CCPA, 1978), it is improper for the Office to refuse to examine that which applicants regard as their invention, unless the subject matter lacks unity of invention.

Should applicant traverse on the ground that the compounds are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the compounds to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C 103(a) of the other.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Rejoinder

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the examiner before the patent issues withdraws the restriction requirement. See MPEP § 804.01.

Telephone Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Taofiq A. Solola, PhD. JD., whose telephone number is (571) 272-0709.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet Andres, can be reached on (571) 272-0867. The fax phone number for this Group is (571) 273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (571) 272-1600.

/Taofiq A. Solola/

Primary Examiner, 1625

June 10, 2009

